Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer

Obese breast cancer patients have a higher risk of lymph node metastasis and a poorer prognosis compared to patients with normal weight. For obese women with node-positive breast cancer, an association between body weight and prognosis remains unclear. In this retrospective study, we analyzed patien...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2015-06, Vol.151 (3), p.569-576
Main Authors: Scholz, Christoph, Andergassen, U., Hepp, P., Schindlbeck, C., Friedl, Thomas W. P., Harbeck, N., Kiechle, M., Sommer, H., Hauner, H., Friese, K., Rack, B., Janni, W.
Format: Article
Language:English
Subjects:
Anthracyclines
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers, Tumor
Body Mass Index
Body weight
Breast cancer
Breast Neoplasms - complications
Breast Neoplasms - drug therapy
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Cancer patients
Cancer research
Cancer therapies
Chemotherapy
Clinical Trial
Clinical Trials, Phase III as Topic
Female
Health aspects
Humans
Kaplan-Meier Estimate
Lymphatic Metastasis
Lymphatic system
Medical prognosis
Medicine
Medicine & Public Health
Menopause
Metastasis
Neoplasm Staging
Obesity
Obesity - complications
Oncology
Postmenopausal women
Prognosis
Randomized Controlled Trials as Topic
Retrospective Studies
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Obese breast cancer patients have a higher risk of lymph node metastasis and a poorer prognosis compared to patients with normal weight. For obese women with node-positive breast cancer, an association between body weight and prognosis remains unclear. In this retrospective study, we analyzed patient data from the Phase-III ADEBAR trial, in which high-risk breast cancer patients (pT1–4, pN2–3, pM0) were randomized into a docetaxel-based versus epirubicin-based chemotherapy regimen. Patients were grouped according to their BMI value as underweight/normal weight (BMI
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-015-3422-3